EU's CHMP recommends label extensions for Viread, Arixtra and M-M-RVAXPRO
This article was originally published in Scrip
The EU's CHMP has endorsed label extensions for Sanofi Pasteur's MMR vaccine M-M-RVAXPRO, Gilead Sciences' antiviral Viread (tenofovir disoproxil fumarate), and GlaxoSmithKline's Factor Xa inhibitor Arixtra (fondaparinux sodium) in its July monthly meeting.
You may also be interested in...
Somaxon Pharmaceuticals and Procter & Gamble Pharmaceuticals are to co-promote Somaxon's insomnia drug Silenor (low-dose doxepin) in the US.
GlaxoSmithKline has begun the Phase III clinical trials programme for its adjuvanted vaccine candidate (GSK1437173A) against herpes zoster for the prevention of shingles.
The EMA has accepted Optimer Pharmaceuticals' MAA for its narrow-spectrum antibiotic fidaxomicin for the treatment of Clostridium difficile infection (CDI) and for the prevention of recurrences of CDI.